The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Nanomedicine(s) under the Microscope
Abstract
Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of delivering new diagnostics, treatments for unmanageable diseases, and opportunities for tissue repair or highly dangerous nanoparticles, nanorobots, or nanoelectronic devices that will wreak havoc in the body. The truth lies firmly between these two extremes. Rational design of "nanomedicines" began almost half a century ago, and >40 products have completed the complex journey from lab to routine clinical use. Here we critically review both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future. Key factors relevant to the design of practical nanomedicines and the regulatory mechanisms designed to ensure safe and timely realization of healthcare benefits are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Cited by
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Biological applications of magnetic nanoparticles
Colombo, M., Carregal-Romero, S., Casula, M. F., Gutiérrez, L., Morales, M. P., Böhm, I. B., Heverhagen, J. T., Prosperi, D., & Parak, W. J. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15337h · Cited by 1,315
Kim, S. E., Zhang, L., Ma, K., Riegman, M., Chen, F., Ingold, I., Conrad, M., Turker, M. Z., Gao, M., Jiang, X., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.164 · Cited by 622
Applications of nanoparticles for diagnosis and therapy of cancer
Baetke, S. C., Lammers, T., & Kiessling, F. (2015) · The British Journal of Radiology · doi:10.1259/bjr.20150207 · Cited by 494
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
Extracellular vesicles: novel promising delivery systems for therapy of brain diseases.
Rufino-Ramos, D., Albuquerque, P. R., Carmona, V., Perfeito, R., Nobre, R. J., & Pereira de Almeida, L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.001 · Cited by 418
Design and properties of functional nanotubes from the self-assembly of cyclic peptide templates
Chapman, R., Danial, M., Koh, M. L., Jolliffe, K. A., & Perrier, S. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35172b · Cited by 309
M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization
Li, H., Feng, Y., Zheng, X., Jia, M., Mei, Z., Wang, Y., Zhang, Z., Zhou, M., & Li, C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.019 · Cited by 259
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.020 · Cited by 245
Nanoparticles for Imaging: top or Flop?
Kiessling, F., Mertens, M. E., Grimm, J., & Lammers, T. (2014) · Radiology · doi:10.1148/radiol.14131520 · Cited by 228
Stepien, G., Moros, M., Pérez-Hernández, M., Monge, M., Gutiérrez, L., Fratila, R. M., las Heras, M. D., Menao Guillén, S., Puente Lanzarote, J. J., Solans, C., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b18648 · Cited by 158
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
Nanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
Challenges of clinical translation in nanomedicine: A qualitative study
Satalkar, P., Elger, B. S., Hunziker, P., & Shaw, D. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.12.376 · Cited by 124
PEG-Graft Density Controls Polymeric Nanoparticle Micelle Stability
Logie, J., Owen, S. C., McLaughlin, C. K., & Shoichet, M. S. (2014) · Chemistry of Materials · doi:10.1021/cm500448x · Cited by 110
Nanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy
Muntimadugu, E., Kommineni, N., & Khan, W. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.010 · Cited by 82
Sakai-Kato, K., Nishiyama, N., Kozaki, M., Nakanishi, T., Matsuda, Y., Hirano, M., Hanada, H., Hisada, S., Onodera, H., Harashima, H., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.259 · Cited by 75
Huesmann, D., Sevenich, A., Weber, B., & Barz, M. (2015) · Polymer · doi:10.1016/j.polymer.2015.04.070 · Cited by 67
Rhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63
Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58
Liposomal glutathione as a promising candidate for immunological rheumatoid arthritis therapy
Kadry, M. O. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02162 · Cited by 29
Bartlett, J. A., Brewster, M., Brown, P., Cabral-Lilly, D., Cruz, C. N., David, R., Eickhoff, W. M., Haubenreisser, S., Jacobs, A., Malinoski, F., et al. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9701-9 · Cited by 25
Metadata
- Authors
- Duncan, R., & Gaspar, R.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-10-26
- Volume
- 8
- Issue
- 6
- Pages
- 2101-2141
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W1965063429
- Cited by
- 981
- References
- 28
- FWCI
- 33.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
